DHH-B

(Dihydrohonokiol-B) 15 mg

DHH-B is studied for its potential to support a calm mood and GABA signaling. Preclinical research suggests it may do so without affecting coordination, memory, or alertness.†



30 Vegetarian capsules	**1** Capsule serving size	**30** Servings per container	Convenient capsule form

RESEARCH AREAS†

Behavioral research
- Anxiety-related behavior
- Confirmation across tests
- Oral activity

Comparison with diazepam
- Motor performance
- Learning and memory
- Sedation-profile research

Mechanism and neuronal research
- GABA-linked signaling
- Neuronal chloride regulation
- Neuronal enzyme activity
- Experimental neuroprotection

RESEARCH HIGHLIGHTS†

BEHAVIORAL RESEARCH

Anxiety-related behavior: Reduced anxiety-like behavior in an established experimental screening test. [1,2]

Confirmation across tests: Demonstrated anxiolytic-like activity in a second behavioral assessment. [2]

Oral activity: Produced measurable effects after oral administration, lasting more than four hours under the tested conditions. [1]

COMPARISON WITH DIAZEPAM

Motor performance: Did not produce the motor-test impairment observed with diazepam under the tested conditions. [3]

Learning and memory: Did not produce the learning and memory impairment observed with diazepam in the experimental assessments. [3]

Sedation-profile research: Did not show diazepam-like enhancement of barbiturate-induced sleep at the tested dose; human sedation effects remain unestablished. [3]

Continued on page 2

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

SUPPLEMENT FACTS

Serving Size: 1 Capsule
Servings Per Container 30

Amount Per Serving		%DV
Dihydrohonokiol-B (DHH-B)	15mg	*

***Daily Value Not Established**

Other Ingredients: Vegetable Capsule (Hypromellose), Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide.

SUGGESTED USE

As a dietary supplement, take 1 capsule once daily, or as directed by your healthcare practitioner.

CAUTIONS

WARNING: For adult use only. This product should not be taken by those who are pregnant or nursing. If you are taking medication or have medical condition, consult with your doctor before use. Keep out of reach of children. Store in a cool, dry place.

QUALITY

Manufactured in a **cGMP compliant** facility.

Made in the USA.

Made with **non-GMO ingredients.**

Free from: salt, soy, yeast, gluten, artificial colors, flavors, and preservatives.

ORDERING

Purchase online at **cscvitamins.com** or by phone **(516) 299-9655**

RESEARCH HIGHLIGHTS† CONTINUED

MECHANISM AND NEURONAL RESEARCH

GABA-linked signaling: Enhanced chloride transport associated with GABA-A receptor activity, supporting a possible mechanism for its behavioral effects. [2]

Neuronal chloride regulation: Reduced ammonia-induced increases in intracellular chloride in cultured nerve cells. [4]

Neuronal enzyme activity: Restored chloride-ATPase activity disrupted by experimental amyloid-beta exposure. [5]

Experimental neuroprotection: Reduced amyloid-beta-associated worsening of glutamate toxicity in cultured nerve cells. [5]

REFERENCES

1. Kuribara H, Kishi E, Kimura M, Weintraub ST, Maruyama Y. Comparative assessment of the anxiolytic-like activities of honokiol and derivatives. Pharmacology Biochemistry and Behavior. 2000;67(3):597–601. doi:10.1016/S0091-3057(00)00401-9.

2. Maruyama Y, Kuribara H, Kishi E, Weintraub ST, Ito Y. Confirmation of the anxiolytic-like effect of dihydrohonokiol following behavioural and biochemical assessments. Journal of Pharmacy and Pharmacology. 2001;53(5):721–725. doi:10.1211/0022357011775848.

3. Kuribara H, Kishi E, Maruyama Y. Does dihydrohonokiol, a potent anxiolytic compound, result in the development of benzodiazepine-like side effects? Journal of Pharmacy and Pharmacology. 2000;52(8):1017–1022. doi:10.1211/0022357001774741.

4. Irie T, Miyamoto E, Kitagawa K, Maruyama Y, Inoue K, Inagaki C. An anxiolytic agent, dihydrohonokiol-B, inhibits ammonia-induced increases in the intracellular Cl− of cultured rat hippocampal neurons via GABAc receptors. Neuroscience Letters. 2001;312(2):121–123. doi:10.1016/S0304-3940(01)02201-7.

5. Liu B, Hattori N, Zhang NY, Wu B, Yang L, Kitagawa K, Xiong ZM, Irie T, Inagaki C. Anxiolytic agent, dihydrohonokiol-B, recovers amyloid beta protein-induced neurotoxicity in cultured rat hippocampal neurons. Neuroscience Letters. 2005;384(1–2):44–47. doi:10.1016/j.neulet.2005.04.081. Corrigendum: Neuroscience Letters. 2005;387(1):57.

10. U.S. Food and Drug Administration. FDA Briefing Document for KPV-Related Bulk Drug Substances: KPV (Free Base) and KPV Acetate. Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026. FDA evaluation.

†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.